GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (NAS:RGNX) » Definitions » Cyclically Adjusted PB Ratio

Regenxbio (Regenxbio) Cyclically Adjusted PB Ratio : 1.26 (As of Jun. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Regenxbio Cyclically Adjusted PB Ratio?

As of today (2024-06-04), Regenxbio's current share price is $14.78. Regenxbio's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $11.69. Regenxbio's Cyclically Adjusted PB Ratio for today is 1.26.

The historical rank and industry rank for Regenxbio's Cyclically Adjusted PB Ratio or its related term are showing as below:

RGNX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.09   Med: 1.44   Max: 2.03
Current: 1.23

During the past years, Regenxbio's highest Cyclically Adjusted PB Ratio was 2.03. The lowest was 1.09. And the median was 1.44.

RGNX's Cyclically Adjusted PB Ratio is ranked better than
58.99% of 656 companies
in the Biotechnology industry
Industry Median: 1.745 vs RGNX: 1.23

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Regenxbio's adjusted book value per share data for the three months ended in Mar. 2024 was $7.966. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $11.69 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Regenxbio Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Regenxbio's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenxbio Cyclically Adjusted PB Ratio Chart

Regenxbio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.60

Regenxbio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 1.60 1.80

Competitive Comparison of Regenxbio's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Regenxbio's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenxbio's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Regenxbio's Cyclically Adjusted PB Ratio falls into.



Regenxbio Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Regenxbio's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=14.78/11.69
=1.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenxbio's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Regenxbio's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=7.966/131.7762*131.7762
=7.966

Current CPI (Mar. 2024) = 131.7762.

Regenxbio Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -1.391 99.070 -1.850
201503 0.000 99.621 0.000
201506 3.358 100.684 4.395
201509 8.432 100.392 11.068
201512 8.240 99.792 10.881
201603 7.920 100.470 10.388
201606 7.413 101.688 9.606
201609 6.807 101.861 8.806
201612 6.109 101.863 7.903
201703 7.039 102.862 9.018
201706 6.861 103.349 8.748
201709 6.257 104.136 7.918
201712 5.849 104.011 7.410
201803 9.384 105.290 11.745
201806 9.829 106.317 12.183
201809 13.838 106.507 17.121
201812 14.088 105.998 17.514
201903 13.303 107.251 16.345
201906 13.458 108.070 16.410
201909 12.714 108.329 15.466
201912 12.170 108.420 14.792
202003 11.297 108.902 13.670
202006 10.669 108.767 12.926
202009 11.113 109.815 13.335
202012 10.080 109.897 12.087
202103 13.046 111.754 15.383
202106 11.920 114.631 13.703
202109 10.793 115.734 12.289
202112 17.845 117.630 19.991
202203 16.046 121.301 17.432
202206 14.605 125.017 15.395
202209 13.024 125.227 13.705
202212 11.922 125.222 12.546
202303 10.701 127.348 11.073
202306 9.304 128.729 9.524
202309 8.254 129.860 8.376
202312 7.078 129.419 7.207
202403 7.966 131.776 7.966

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regenxbio  (NAS:RGNX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Regenxbio Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Regenxbio's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenxbio (Regenxbio) Business Description

Industry
Traded in Other Exchanges
Address
9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).
Executives
Kenneth T. Mills director, officer: See Remarks C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Vittal Vasista officer: See Remarks C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jennifer Zachary director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steve Pakola officer: Chief Medical Officer C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Allan M. Fox director, 10 percent owner C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jean Bennett director C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
George V Migausky director C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Patrick J. Christmas officer: Senior VP, General Counsel C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Curran Simpson officer: SVP of Technical Operations C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Hayden Donald J Jr director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Olivier Danos officer: Chief Scientific Officer C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Luke M Beshar director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stephen Yoo officer: Chief Medical Officer C/O REGENXBIO INC,, 9600 BLACKWELL ROAD, SUITE 210, ROCKVILLE MD 20850
Alexandra Glucksmann director C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Daniel Tasse director C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809